The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 struggles, but European peers rise

Thu, 23rd Feb 2023 17:00

(Alliance News) - Stock prices in London closed mixed on Thursday, with blue-chips ending in the red on renewed concerns of higher rates in the US, as well as a host of stocks going ex-dividend.

The FTSE 100 index closed down 22.91 points, 0.3%, at 7,907.72. However, the FTSE 250 ended up 110.20 points, 0.6%, at 19,790.49, and the AIM All-Share closed up 0.4%, or 3.23 points, at 855.51.

The Cboe UK 100 ended down 0.1% at 792.22, the Cboe UK 250 closed up 0.6% at 17,274.38, and the Cboe Small Companies ended up 0.4% at 13,987.18.

London's blue-chip index struggled after minutes from the most recent Federal Open Market Committee meeting revealed that US central bank officials anticipate further increases in interest rates will be needed to ensure their inflation target is met. That is despite signs pricing pressures are easing.

Stocks in New York initially shrugged aside the renewed rate concerns and pushed higher, but fell back to trade in negative territory at the time of the London equities close. The Dow Jones Industrial Average was down 0.3%, the S&P 500 index down 0.2%, and the Nasdaq Composite down 0.3%.

In European equities on Thursday, the mood was brighter. The CAC 40 in Paris ended up 0.3%, while the DAX 40 in Frankfurt closed up 0.5%.

Putting pressure on the FTSE 100 were share price falls for pharmaceutical firms GSK and AstraZeneca. The duo fell 1.6% and 2.5% after going ex-dividend, meaning new buyers would not qualify for their latest payout.

In London, Rolls-Royce topped the list of FTSE 100 risers, soaring 24%, after better-than-expected full-year results. New Chief Executive Tufan Erginbilgic unveiled a seven-pronged transformation plan to further improve performance and reduce debt.

Broker Shore Capital said the results, "show good progress towards improved profitability with Civil Aerospace performing better than expected".

Susannah Streeter, head of money and markets, Hargreaves Lansdown said, "investors have cheered the turnaround and welcomed the strategic plan".

Streeter said: "[The] restructuring plan announced is likely to see changes made to the global footprint, some divisions scaled back, and investment re-routed into other operations."

"The company will be helped in the meantime by the re-opening in China, with its core business of manufacturing and maintaining jet engines set to be boosted by renewed popularity of longer haul routes."

WPP climbed 3.4%. The London-based advertising and communications company said revenue in 2022 rose 13% to GBP14.43 billion from GBP12.80 billion in 2021. Pretax profit jumped 22% to GBP1.16 billion from GBP951 million.

Shares in John Wood Group soared 29% after it said after the market close Wednesday that it had rebuffed bid approaches from Apollo Global Management.

The FTSE 250 company said that it had turned down all unsolicited proposals from the US firm, with the most recent approach in late January valuing it at GBP1.59 billion. The cash offer for all of its shares was worth 230 pence each.

The company said: "The board carefully considered each of the proposals, together with its financial advisers, and has engaged on a limited basis with Apollo. The board unanimously rejected each of the proposals, having concluded that they each significantly undervalued the repositioned group’s prospects."

Mondi shares fell 4.8% despite strong 2022 results. The paper and packaging firm reported a pretax profit of EUR1.56 billion in 2022, up from EUR712 million in 2021. Revenue jumped 28% to EUR8.90 billion from EUR6.97 billion.

But the FTSE 100 listed firm warned it continues to see softer demand and pricing, however, despite declining input costs.

Shares in SigmaRoc leapt 7.2% after the quarried materials group successfully raised GBP30 million through a placing of shares at 54 pence each.

The AIM-listed company's management team actively participated in the structuring and allocation of the fundraising.

Proceeds from the placing will part fund 10 potential near-term strategic acquisition opportunities and four organic growth and carbon footprint reduction projects.

Taken together, the acquisitions and organic investment projects are anticipated, should they all complete, to generate approximately GBP42 million of net revenue.

The pound was quoted at USD1.2023 at the London equities close Thursday, down compared to USD1.2066 at the equities close on Wednesday.

The euro stood at USD1.0593 at the European equities close Thursday, down against USD1.0629 at the same time on Wednesday. Against the yen, the dollar was trading at JPY134.72, up compared to JPY134.67 late Wednesday.

Capital Economics expects the dollar to strengthen further.

"While US economic resilience may keep the green back strong in the near term, we still think that recessions in most advanced economies and souring appetite for risk will ultimately be the factor that pushes the dollar back towards its cyclical high later this year," CE analysts said.

Brent was quoted at USD81.71 a barrel at the London equities close Thursday, up from USD81.24 Wednesday. Gold was quoted at USD1,821.05 an ounce, down against USD1,825.00.

Friday's economic calendar has a Japanese inflation reading overnight, before US core personal consumption expenditures data at 1330 GMT.

The local corporate calendar has annual results from British Airways parent International Consolidated Airlines Group and half-year numbers from veterinary services provider CVS Group.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.